Liu Y - Search Results

1

SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression.

Quan S, Li N, Lian S, Wang Y, Liu Y, Liu J, Zhang Z, Gao D, Li Y. Quan S, et al. Among authors: liu j, liu y. Int Immunopharmacol. 2024 Oct 25;140:112756. doi: 10.1016/j.intimp.2024.112756. Epub 2024 Jul 30. Int Immunopharmacol. 2024. PMID: 39083932 Free article.

2

IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway.

Chen X, Zhu X, Shen X, Liu Y, Fu W, Wang B. Chen X, et al. Among authors: liu y. Immunopharmacol Immunotoxicol. 2023 Jun;45(3):370-377. doi: 10.1080/08923973.2022.2150636. Epub 2023 Mar 27. Immunopharmacol Immunotoxicol. 2023. PMID: 36972188

3

Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix.

Liu Y, Qi Y. Liu Y, et al. Int Immunopharmacol. 2020 Oct;87:106774. doi: 10.1016/j.intimp.2020.106774. Epub 2020 Jul 27. Int Immunopharmacol. 2020. PMID: 32731178

4

Fibrinogen-like protein 2 in inflammatory diseases: A future therapeutic target.

Fu L, Liu Z, Liu Y. Fu L, et al. Among authors: liu z, liu y. Int Immunopharmacol. 2023 Mar;116:109799. doi: 10.1016/j.intimp.2023.109799. Epub 2023 Feb 8. Int Immunopharmacol. 2023. PMID: 36764282 Free article. Review.

5

Sevoflurane exerts protection against myocardial ischemia-reperfusion injury and pyroptosis through the circular RNA PAN3/microRNA-29b-3p/stromal cell-derived factor 4 axis.

An L, Zhong Y, Tan J, Liu Y, Li A, Yang T, Wang S, Liu Y, Gao H. An L, et al. Among authors: liu y. Int Immunopharmacol. 2023 Jul;120:110219. doi: 10.1016/j.intimp.2023.110219. Epub 2023 Jun 2. Int Immunopharmacol. 2023. PMID: 37270931

6

ROR1/STAT3 positive feedback loop facilitates cartilage degeneration in Osteoarthritis through activation of NF-κB signaling pathway.

Huang W, Tang H, Liu Y, Li W, Shimu AS, Li B, Zhu C. Huang W, et al. Among authors: liu y. Int Immunopharmacol. 2023 Aug;121:110433. doi: 10.1016/j.intimp.2023.110433. Epub 2023 Jun 19. Int Immunopharmacol. 2023. PMID: 37343369

7

Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.

Pu Y, Zhao Y, Qi Y, Liu Y, Zhang M, Xiao X, Lyu H, Meng J, Zhu H, Xu K, Han W, Zhao M. Pu Y, et al. Among authors: liu y. Int Immunopharmacol. 2024 Mar 30;130:111761. doi: 10.1016/j.intimp.2024.111761. Epub 2024 Feb 28. Int Immunopharmacol. 2024. PMID: 38422769

8

Prognosis and immunotherapy in melanoma based on selenoprotein k-related signature.

Liu Y, Xia H, Wang Y, Han S, Liu Y, Zhu S, Wu Y, Luo J, Dai J, Jia Y. Liu Y, et al. Int Immunopharmacol. 2024 Aug 20;137:112436. doi: 10.1016/j.intimp.2024.112436. Epub 2024 Jun 9. Int Immunopharmacol. 2024. PMID: 38857552

9

VX-509 (Decernotinib)-modified tolerogenic dendritic cells alleviate experimental autoimmune neuritis by promoting Th17/Treg rebalance.

Li J, Chen S, Shi J, Yang F, Zhang G, Zhou Y, Kong Y, Luo X, Liu Y, Xu Y, Wang Y. Li J, et al. Among authors: liu y. Int Immunopharmacol. 2024 Sep 10;138:112597. doi: 10.1016/j.intimp.2024.112597. Epub 2024 Jul 2. Int Immunopharmacol. 2024. PMID: 38955025

10

Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy.

Huang T, Peng Y, Liu R, Ma B, Chen J, Wei W, Zhong W, Liu Y, Guo S, Han H, Zhou F, Zhang Z, He L, Dong P. Huang T, et al. Among authors: liu y, liu r. Int Immunopharmacol. 2024 Dec 5;142(Pt B):113106. doi: 10.1016/j.intimp.2024.113106. Epub 2024 Sep 16. Int Immunopharmacol. 2024. PMID: 39288623

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

209,185 results

Search Page

Filters